Developing a manufacturing process to deliver a cost effective and stable liquid human rotavirus vaccine
Ahd Hamidi, Femke Hoeksema, Pim Velthof, Angelique Lemckert, Gert Gillissen, Alfred Luitjens, Julie E Bines, Swathi R Pullagurla, Prashant Kumar, David B Volkin, Sangeeta B Joshi, Menzo Havenga, Wilfried AM Bakker, Christopher Yallop
VACCINE | ELSEVIER SCI LTD | Published : 2021
Despite solid evidence of the success of rotavirus vaccines in saving children from fatal gastroenteritis, more than 82 million infants worldwide still lack access to a rotavirus vaccine. The main barriers to global rotavirus vaccine coverage include cost, manufacturing capacity and suboptimal efficacy in low- and lower-middle income countries. One vaccine candidate with the potential to address the latter is based on the novel, naturally attenuated RV3 strain of rotavirus, RV3-BB vaccine administered in a birth dose strategy had a vaccine efficacy against severe rotavirus gastroenteritis of 94% at 12 months of age in infants in Indonesia. To further develop this vaccine candidate, a well-do..View full abstract
Awarded by Bill and Melinda Gates Foundation
This work was funded by the Bill and Melinda Gates Foundation (grant number: OPP1148427).